Lupus nephritis: the evolving role of novel therapeutics - sprookjes - yvandenbroek - TriplyDB

Lupus nephritis: the evolving role of novel therapeutics

Lupus nephritis: the evolving role of novel therapeutics

http://www.wikidata.org/entity/Q26998390

about

Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells The pathogenesis, diagnosis and treatment of lupus nephritis.Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis.Early-stage lupus nephritis treated with N-acetylcysteine: A report of two cases.Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.Genetics of Lupus Nephritis: Clinical Implications.Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis Isoflurane attenuates murine lupus nephritis by inhibiting NLRP3 inflammasome activation.IL-6 Trans-Signaling Drives Murine Crescentic GN What is damaging the kidney in lupus nephritis?Lupus nephritis in children - 10 years' experience.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms.Mycophenolate mofetil for lupus nephritis: an update.Towards new avenues in the management of lupus glomerulonephritis.T cells and IL-17 in lupus nephritis.The safety of isotretinoin in patients with lupus nephritis: a comprehensive review.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.Excessive activation of the TLR9/TGF-β1/PDGF-B pathway in the peripheral blood of patients with systemic lupus erythematosus.The kidney biopsy in lupus nephritis: is it still relevant?Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis.Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.Lupus nephritis: through the looking-glass.Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.Renal Tubular Complement 3 Deposition in Children with Primary Nephrotic Syndrome.

P2860

Q26746146-F8CA2D5A-3CF6-44C2-9128-28A761A19007 Q28543539-F436D0CA-38BA-4BF5-89DD-9AC243900CBE Q30596968-2AAE516E-0672-4DE9-904C-DFB34ED65899 Q35249467-25DC4DFB-F99E-436F-82C2-C5415E5BFFD6 Q35853913-6D454E41-5268-45D8-A3E1-6AECEDF196AC Q35871258-AD4FF859-76D5-45B1-8C84-E92C05086C76 Q36186103-7F4B846D-B9F7-40EA-8F5C-68C18EE9869F Q36275483-5ABF61A0-37F4-4DD3-8EC8-FD2A4E25A3AC Q36300008-DD951E9A-FDDB-4BDE-9218-6EF2AF803858 Q36340132-19B981E6-9935-4550-B72A-6867AF8D7BEE Q36411613-47C1FB0B-D736-4497-BE44-891D7D444330 Q36417912-392711D1-735E-45E1-9548-120F09237506 Q36765221-71181405-B922-4B50-A3AB-E5BFB9E07B3C Q37399315-04A3E916-911E-4C1B-ABA5-F783025273C2 Q37456300-D1131908-6FB7-4794-995B-8DCE15282950 Q37602101-88A72217-06DF-4A2C-B6EC-205654F1540C Q38585887-5C22207F-453F-458F-9B9C-7CBA1F564A8A Q38686467-ADFC045F-9E1B-404F-A64B-3584A714FA62 Q38816316-FFF44003-016B-4276-8C3A-C9E47FF21C8B Q38830159-5446C98C-A99B-426B-BAD9-58FF6449D20F Q39218839-5F0FBAA5-E9AF-477B-B259-43B374B5790C Q39229321-C1C969EF-5D80-436E-9630-774A12BB0274 Q39410103-0174BC69-5AAB-48C0-B53C-17E2951ABFF0 Q40053971-22D08921-4DFF-4836-A652-E1A6B6540247 Q42135044-94E77DFC-75AB-49EB-9D46-38401D9589AB Q42843702-F544C141-C961-4546-BD46-C201803B2C7D Q48056780-1D3ACF64-5CB7-4228-87D3-B429359A6D1D Q48361761-FC983F94-F36A-4675-914A-0044B5E5E98C Q50493859-858505E5-424E-437D-ABA0-BC4DD7F04ABA Q53602451-4C6D00F3-8775-429A-9559-E80013261983 Q55314394-B5B3D9E2-9751-411C-B5AE-904B2D279D1E Q55555541-200D3812-6337-4741-9732-C43C7A488AB5

P2860

Lupus nephritis: the evolving role of novel therapeutics

http://www.wikidata.org/entity/Q26998390

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Lupus nephritis: the evolving role of novel therapeutics

@ast

Lupus nephritis: the evolving role of novel therapeutics

@en

Lupus nephritis: the evolving role of novel therapeutics

@nl

type

label

Lupus nephritis: the evolving role of novel therapeutics

@ast

Lupus nephritis: the evolving role of novel therapeutics

@en

Lupus nephritis: the evolving role of novel therapeutics

@nl

prefLabel

Lupus nephritis: the evolving role of novel therapeutics

@ast

Lupus nephritis: the evolving role of novel therapeutics

@en

Lupus nephritis: the evolving role of novel therapeutics

@nl

P1433

Q26998390-A195006A-3276-46A3-878F-125B8C3B12CB

P1476

Q26998390-89A069E2-EC08-4C18-92C2-B5B7C7BC1347

P2093

Q26998390-3F21A429-B0AB-4478-A357-6A5CA360C8C0

Q26998390-D0D4DE54-FE84-4F5A-A480-D356BBAB8670

P2860

Q26998390-009B2081-69F1-4697-B267-90AD2C44F347

Q26998390-009E7BED-41F4-40C0-9CB1-BEC68904B5F8

Q26998390-01113A7D-734E-441A-BCD6-29DEECA9E295

Q26998390-022727EA-E654-40C0-8BC2-5886122656F6

Q26998390-022A8EB8-FC6A-4FEE-86BA-6167CBBB1C69

Q26998390-0348CBFD-0DAE-4AAF-B188-26AFABEC4BE6

Q26998390-04AD687F-541A-4F77-8973-184089608456

Q26998390-0991C1D3-2CA8-43B7-9A2D-77C19B962EDA

Q26998390-0B924F51-1C7B-4BCE-BBCF-F742C43FFA66

Q26998390-0F19B6DD-8734-4090-A76E-77D1448BDBC1

P304

Q26998390-34C1948C-A59E-473D-B83E-C1E6C9C22FF5

P31

Q26998390-01B8D414-EBEA-4BF9-9A95-9EB380FA0B36

P3181

Q26998390-B42F38A4-2B8E-44EB-BD1A-93E48110CCEC

P356

Q26998390-DA7903D2-FC63-4B0D-9D76-3166E546E983

P407

Q26998390-949CBBE5-9081-4C74-8294-5ACE43CD6C86

P433

Q26998390-5A23D46E-BE4C-4D44-AC5C-3A5379233DB4

P478

Q26998390-0E7F88E8-BAE2-41F7-8892-F9AD140CA207

P577

Q26998390-60B379B5-446E-4D0E-ABF9-EA6966D15BD5

P698

Q26998390-6E088B72-2E74-41F7-A9BF-97D7B6619B79

P932

Q26998390-A90DBC8C-41F4-4A29-A095-103E28982347

P3181

P356

J.AJKD.2013.11.023

P1433

American Journal of Kidney Diseases

P1476

Lupus nephritis: the evolving role of novel therapeutics

@en

P2093

Brad H. Rovin

http://www.w3.org/2001/XMLSchema#string

Samir V. Parikh

http://www.w3.org/2001/XMLSchema#string

P2860

A Toll-like receptor recognizes bacterial DNA

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

Rationale for interleukin-6 blockade in systemic lupus erythematosus

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

IL-17 family cytokines and the expanding diversity of effector T cell lineages

P304

677-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2620931

http://www.w3.org/2001/XMLSchema#string

P356

10.1053/J.AJKD.2013.11.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24411715

http://www.w3.org/2001/XMLSchema#string

P932

4159074

http://www.w3.org/2001/XMLSchema#string